renal cancer
Conditions
Interventions
In the first week at hospitalization I intravenously inject Cyclophosphamide 300 mg / m 2 on day 1. On day 2-5, infusion of 700 thousand units of IL-2 in 1 or 2 divided doses a day. On the 2nd to 4t
Sponsors
Osaka City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients who used molecularly targeted drugs for curative resection or metastatic renal cell carcinoma (2) Patients with one or more measurable lesions according to RECIST v.1.1 (3) Patients over 20 years old and under 80 (4) Patients with ECOG Performance Status (PS) 0-1 (5) Patients with appropriate bone marrow function, liver function
Exclusion criteria
Exclusion criteria: 1) Patients with a history of hypersensitivity to Cyclophosphamide and IL-2 2) Pregnant women, lactating women, pregnant women, lactating women, patients with a plan to go out 3) Patients receiving adrenocortical hormone drug and pentostatin 4) Patients with metastatic lesions in the brain 5) Patients who are deemed inappropriate for the subject doctor in this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response efficiency in the therapy of IL-2 after preceding Cyclophosphamide | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) progression-free survival in the therapy of IL-2 after preceding Cyclophosphamide (Progression-free Survival, PFS) 2) Safety in the therapy of IL-2 after preceding Cyclophosphamide 3) On the change of various lymphocytes of peripheral blood | — |
Countries
Japan
Contacts
Public ContactSatoshi Tamada
Osaka City University Urology
Outcome results
None listed